Please try another search
Investing.com - SurModics (NASDAQ: SRDX) reported second quarter EPS of $0.07, $0.42 better than the analyst estimate of $-0.35. Revenue for the quarter came in at $32M versus the consensus estimate...
Earnings Conference Call and Webcast Will Begin at 7:00 am (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...
Surmodics, Inc. (SRDX) has reported a significant 23% year-over-year increase in total revenue, reaching $30.6 million for the first quarter of fiscal year 2024. Excluding the SurVeil DCB license fee...
Investing.com - SurModics (NASDAQ: SRDX) reported first quarter EPS of $-0.06, $0.27 better than the analyst estimate of $-0.33. Revenue for the quarter came in at $30.6M versus the consensus...
Investing.com - SurModics (NASDAQ: SRDX) reported fourth quarter EPS of $0.53, $0.37 better than the analyst estimate of $0.16. Revenue for the quarter came in at $28M versus the consensus estimate...
Investing.com - SurModics (NASDAQ: SRDX) reported third quarter EPS of $0.52, $0.98 better than the analyst estimate of $-0.46. Revenue for the quarter came in at $52.5M versus the consensus...
Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Oracle, Devon Energy, SurModics, and Estee Lauder.InvestingPro subscribers got this news before...
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the company’s Pounce™ LP (Low Profile)...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review